Catheter ablation was not the first-line treatment for supraventricular tachycardia (SVT) for most patients referred to a tertiary center, a study shows, with investigators suggesting the procedure is ...
Researchers at RIT are developing non-invasive technology that will better assess cardiac tissue response to thermal energy, a common therapy approach for both cancer and cardiac arrhythmia treatments ...
Atrial fibrillation (AF) remains the most common sustained cardiac arrhythmia, posing significant public health challenges due to its association with stroke, heart failure and diminished quality of ...
Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, and CardioFocus, Inc., a medical device company dedicated to advancing ...
Stereotaxis CEO David Fischel said the precision, stability and safety profile of robotics are a good fit for pulsed field ...
HAYWARD, Calif.--(BUSINESS WIRE)-- Pulse Biosciences, Inc. (Nasdaq: PLSE), a company primarily focused on leveraging its novel and proprietary CellFX Nanosecond Pulsed Field Ablation (nsPFA) ...
A group of engineers from Northwestern and The George Washington University recently developed new medical instruments with smart sensors that improve the diagnoses and treatments of cardiac diseases.
Company’s proprietary system used to treat initial five patients in first-in-human feasibility study for patients with atrial fibrillation HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback